Clinical trials: HPV-16/18

Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

• Completed
• Age: 9 to 26 years
• Phase 3
• Vaccines
• Injection or infusion
• Results posted

This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil® (quadrivalent human papillomavirus [qHPV] vaccine, V501) in Chinese girls aged 9-19 years and young women aged 20-26 years.

Trial name

NCT03493542

Testing

V501

Where

China

Volunteers

766 people, healthy volunteers welcome

Sponsor

Merck Sharp & Dohme LLC